Liau Siong-Seng, Cariati Massimiliano, Noble David, Wilson Charles, Wishart Gordon C
Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, UK.
Ann R Coll Surg Engl. 2010 Oct;92(7):562-8. doi: 10.1308/003588410X12699663903476. Epub 2010 Jun 1.
The risk of ipsilateral breast tumour recurrence (IBTR) following breast conservation surgery (BCS) for invasive breast cancer (IBC) and radiotherapy is dependent on patient-, tumour- and treatment-related variables. In the Cambridge Breast Unit, breast conserving surgery has been performed with a target radial margin of 5 mm for IBC, in combination with 40-Gy hypofractionated (15 fractions) breast radiotherapy, since 1999.
An audit was performed of cases treated between 1999 and 2004. A total of 563 patients underwent BCS for invasive breast cancer with 90.4% receiving radiotherapy (RT) and 60.4% of patients receiving boost RT (3 fractions of 3-Gy).
After a median follow-up of 58 months, five of the 563 (0.9%) patients developed IBTR. The 5-year actuarial IBTR rate was 1.1%. In terms of distant disease recurrence (DDR), 29 of the 563 (5.2%) had DDR during follow-up, giving a 5-year actuarial DDR rate of 5.4%. The 5-year breast cancer specific survival was 95%, with the poorer NPI groups having worse breast cancer specific survival (Log-rank, P<0.0001). More importantly, patients with IBTR had a shorter breast cancer-specific survival than those who were IBTR-free (Log-rank, P<0.0001).
Our treatment regimen, combining BCS with a 5-mm target margin and hypofractionated 40-Gy RT, results in an extremely low rate of IBTR, and compares favourably with the target IBTR rate of <5% defined by the Association of Breast Surgeons (ABS) at BASO guidelines.
浸润性乳腺癌(IBC)保乳手术(BCS)联合放疗后同侧乳腺肿瘤复发(IBTR)的风险取决于患者、肿瘤和治疗相关变量。自1999年以来,在剑桥乳腺中心,对IBC进行保乳手术时的目标切缘为5毫米,并联合40Gy的大分割(15次分割)乳腺放疗。
对1999年至2004年间治疗的病例进行了一项审计。共有563例患者接受了浸润性乳腺癌的保乳手术,90.4%的患者接受了放疗(RT),60.4%的患者接受了追加放疗(3次3Gy分割)。
中位随访58个月后,563例患者中有5例(0.9%)发生了IBTR。5年精算IBTR率为1.1%。就远处疾病复发(DDR)而言,563例患者中有29例(5.2%)在随访期间出现DDR,5年精算DDR率为5.4%。5年乳腺癌特异性生存率为95%,NPI较差的组乳腺癌特异性生存率较差(对数秩检验,P<0.0001)。更重要的是,发生IBTR的患者的乳腺癌特异性生存率低于未发生IBTR的患者(对数秩检验,P<0.0001)。
我们将保乳手术与5毫米目标切缘和40Gy大分割放疗相结合的治疗方案导致IBTR发生率极低,与乳腺外科医生协会(ABS)在BASO指南中定义的目标IBTR率<5%相比具有优势。